Nexium Approved For Lowering Risk Of NSAID-Related Ulcers
This article was originally published in The Pink Sheet Daily
Executive Summary
The supplemental approval allows AstraZeneca to position Nexium as an alternative to switching patients to a COX-2 to reduce the risk of gastric ulcers associated with continuous NSAID therapy. Nexium NSAID-related ulcer "healing" indication is "approvable."